Approach and Progress
What Precision Therapeutics Means to Us
Human genetics is at the core of our therapeutic and development strategies. To build our pipeline, we focused on patients first — particularly patients with a high genetic risk profile. We assessed the functional implications of their underlying mutations. We then matched each molecular abnormality with an appropriate therapeutic candidate. We are currently pursuing three distinct genetically defined patient populations in our ocular portfolio.
A Truly Multimodal Process
We’re focused on finding the best therapeutic solutions for patients — and we’re not limited to a single approach. We have carefully selected a panel of technologies well-suited to each target that human genetics has defined for us. This strategy has resulted in a broad and diverse pipeline, including monoclonal antibodies, recombinant proteins and gene therapies.
Our broad pipeline spans three genetically-defined targets in our ocular portfolio and three modalities including recombinant proteins, monoclonal antibodies, and gene therapies.